Narcolepsy without cataplexy

This study tests whether clarithromycin, an antibiotic, can reduce excessive daytime sleepiness in people with narcolepsy or idiopathic hypersomnia. Participants receive either clarithromycin or a placebo for 14 days. Researchers will measure changes in sleepiness, brain activity…

This study compares a new mass spectrometry technique to the standard radioimmunoassay for measuring orexin-A levels in cerebrospinal fluid. Orexin-A is a key brain chemical that is low in people with type 1 narcolepsy. The study involves 117 people with excessive daytime sleepin…

This study tests two behavioral therapies—imagery rehearsal therapy (IRT) and targeted dream control (TDC)—to reduce nightmares in adults with narcolepsy. Participants attend therapy sessions, keep a daily sleep log, and complete questionnaires. Some Chicago-area participants als…

This study tested a six-session behavioral therapy that teaches people with narcolepsy type 1 how to become aware during dreams (lucid dreaming) and control frightening images. Ninety-eight adults took part, with half receiving the therapy and half getting standard care. The goal…

This phase 2 study tested an experimental drug called ALKS 2680 in 93 adults with narcolepsy type 2, a condition causing severe daytime sleepiness. Participants took either the drug or a placebo daily to see if it safely improved their ability to stay awake. The trial is now comp…

This early-phase study tested a new slow-release form of pitolisant (HBS-201) in 46 adults with narcolepsy. The goal was to see if starting at a full dose is tolerable. Participants took the drug for 14 days, and researchers tracked side effects and dropouts.

This study tested a website designed to help teenagers with narcolepsy or idiopathic hypersomnia and their families understand and improve social relationships. Twenty-five teens and their parents reviewed the website's content, which included animations, patient stories, and exp…